CORDIS
EU research results

CORDIS

English EN

Interdisciplinary training network on the purinergic P2X7 receptor to control neuroinflammation and hyperexcitability in brain diseases.

Objective

Brain disorders affect ~179 million people and their families in Europe alone, with an annual cost to the taxpayer estimated at €800 billion- a greater economic burden than cardiovascular disease and cancer combined. Despite diverse etiology, overlap in clinical symptoms and comorbidities between brain disorders suggests shared patho-mechanisms. In particular, hyperexcitible states driven by glial activation and neuroinflammation appear near ubiquitous. Targeting these mechanisms offers the potential to ameliorate symptoms and reverse disease progression across a broad span of brain disorders. Functioning as a gatekeeper to neuroinflammation and mechanistic link between neuronal hyperexcitability and glial activation, the ATP-gated, ionotropic purinergic P2X7 receptor (P2X7R) offers the most promising target for pharmacological intervention in the neuroinflammation-hyperexcitability pathway, to date. With breakthroughs in understanding P2X7R function, highly promising effects demonstrated for antagonists in models of brain disease and vast investment in P2X7R-related drug development programmes, now is the perfect time to pool resources. PurinesDX brings together global leaders in translational research in purinergic signalling, Europe’s leading clinical specialists in a broad range of brain diseases, and industrial partners specializing in drug and biomarker development. Sharing unique genetic tools, newly developed diagnostic devices and novel, selective and brain-stable P2X7R antagonists, the synergism facilitated within PurinesDX will extend to the training of an urgently needed new generation of highly skilled, innovative, creative and entrepreneurial scientists. Alongside the provision of this interdisciplinary, international and intersectoral environment, an original and high level training in state-of-the-art neuroscience will be provided, nurturing a cohort of highly competitive researchers with potential to drive a new era of neuroscience research.

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 531 349,20

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 249 216,48

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

EU Contribution

€ 495 745,92

INSTITUTE OF EXPERIMENTAL MEDICINE - HUNGARIAN ACADEMY OF SCIENCES

Hungary

EU Contribution

€ 447 827,04

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 249 216,48

CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS

Spain

EU Contribution

€ 247 872,96

SARISSA BIOMEDICAL LIMITED

United Kingdom

EU Contribution

€ 546 575,76

BIOTALENTUM TUDASFEJLESZTO KFT

Hungary

EU Contribution

€ 223 913,52

FUNDACION TEOFILO HERNANDO

Spain

EU Contribution

€ 495 745,92

Partners (12)

Sort alphabetically

Expand all

JANSSEN PHARMACEUTICA NV

Belgium

Affectis Phamaceuticals AG

Germany

Dr. Seibt Genomics GmbH

Germany

Longboat Clinical Ltd

Ireland

FUNDACION CENTRO DE INVESTIGACION DE ENFERMEDADES NEUROLOGICAS

Spain

FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Spain

SEMMELWEIS EGYETEM

Hungary

Epilepsiezentrum Frankfurt Rhein-Main

Germany

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

THE UNIVERSITY OF WARWICK

United Kingdom

UNIVERSIDAD AUTONOMA DE MADRID

Spain

SZENT ISTVAN UNIVERSITY

Hungary

Project information

Grant agreement ID: 766124

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 487 463,28

  • EU contribution

    € 3 487 463,28

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland